Pharmacoeconomic evaluation of medical treatment of epilepsy: Where do we stand?

Acta Neurologica Belgica

Volumn 99, Issue 4, 1999, Pages 239-246

  Levy, Pierre ^a  

^a UNIVERSITÉ PARIS DAUPHINE   (France)

Author keywords

Adjuvant therapy; Antiepileptics; Cost minimisation; Cost utility; Monotherapy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; EPILEPSY;

EID: 0033374452     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. BAKER G. A., NASHEF L., VAN HOUT B. A. Current issues in the management of epilepsy: the impact of frequent seizures on cost of illness, quality of life, and mortality. Epilepsia, 1997, 38 (suppl. 1): S1-S8.
2. BEGLEY C. E., ANNEGERS J. F., LAIRSON D. R., REYNOLDS T. F. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia, 1994, 35 (6): 1230-1243.
3. BERAN R. G., PACHLATKO Ch. Report of the International League Against Epilepsy Commission on economic aspects of epilepsy. Epilepsia, 1996, 37 (5): 506-508.
4. BERAN R. G., PACHLATKO Ch. Final report of the ILAE Commission on economic aspects of epilepsy, 1994-1997. Epilepsia, 1997, 38 (2): 1359-1362.
5. BINNIE C. D. Design of clinical antiepileptic drug trials. Seizure, 1995, 4: 187-192.
6. CHADWICK D. Epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57: 264-277.
7. CHADWICK D. Measuring antiepileptic therapies: the patients Vs the physician viewpoint. Neurology, 1994, 44 (suppl. 8): S24-S28.
8. CHADWICK D. W. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia, 1997, 38 (suppl. 1): S59-S62.
9. COCKERELL O. C., HART Y. M., SANDER J. W. A. S., SHORVON S. D. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Research, 1994, 18: 249-260.
10. COCKERELL O. C., SHORVON S. D. The economic cost of epilepsy. In: The treatment of epilepsy. SHORVON S., DREIFUSS F., FISH D., THOMAS D. London, Blackwell Science, 1996.
11. DICHTER M. A., BRODIE M. J. New antiepileptic drugs. The New England Journal of Medicine, 1996, 334 (24): 1583-1590.
12. EADIE M. J. The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Clin. Pharmakinet, 1995, 29 (1): 29-35.
13. GRIFFIN J., WYLES M. Epilepsy towards tomorrow, Office of Health Economics, 1991.
14. HEANEY D. C., SHORVON S. D., SANDER J. W. A. S. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia, 1998, 39 (Suppl. 3): S19-S25.
15. HOLLIDAY S. M., BENFIELD P., PLOSKER G. L. Fos-phenytoin - Pharmacoeconomic implications of therapy. Pharmacoeconomics, 1998, 14 (6): 685-690.
16. HUGUES D., COCKERELL O. C. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure, 1996, 5: 89-95.
17. JACOBY A. Assessing quality of life in patients with epilepsy. Pharmacoeconomics, 1996, 9 (5): 399-416.
18. JACOBY A., BUCK D., BAKER G. A., MCNAMEE P. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia, 1998, 39 (7): 776-786.
19. JOHNSON W. G. The costs of epilepsy and cost-based evaluations of anticonvulsants. Pharmacoeconomics, 1997, 12 (4): 446-459.
20. KOCHEN S. Costing of antiepileptic drugs. The Lancet, 1996, 347 (January 27): 266.
21. MATSUO F., BERGEN D., FRAUGHT E. et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology, 1993, 43: 2284-2291.
22. MESSORI A., TRIPPOLI S., BECAGLI P. et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. European Journal of Clinical Pharmacology, 1998, 53: 421-427.
23. MURRAY M. I., HALPERN M. T., LEPPIK I. E. Cost of refractory epilepsy in adults in the USA. Epilepsy Research, 1996, 23: 139-148.
24. NAVARRO R. P., ASHRAF T. Cost analysis of carbamazepine, phenytoin, and valproate for usein complex partial seizures. Medical Interface, 1993, 6 (March): 113-118.
25. NOWACK W. J. Epilepsy: a costly misdiagnosis. Clinical Electroencephalography, 1997, 28 (4): 225-228.
26. O'NEILL B. A., TRIMBLE M. R., BLOOM D. S. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options. Seizure, 1995, 4: 37-44.
27. PACHLATKO C. Economic aspects of epilepsy: the state of the art. In: Economic evaluation of epilepsy management. PACHLATKO C., BERAN R. G., LIBBEY John (eds.), 1996.
28. PACHLATKO C. The cost of epilepsy care to the community. Seizure, 1997, 6 (6): 415-417.
29. REINHARZ D., KENNEDY W., CONTRANDRIOPOULOS A.-P. et al. The economic effects of introducing vigabatrin, a new antiepileptic medication. Pharmacoeconomics, 1995, 8 (5): 400-409.
30. REYNOLDS E. H. Foreword. In: Economic evaluation of epilepsy management. PACHLATKO C., BERAN R. G., LIBBEY John, 1996.
31. SANDER J. W. A., SHORVON S. D. Incidence and prevalence studies in epilepsy and their methodological problems: a review. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50: 829-839.
32. SHAKESPEARE A., SIMEON G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure, 1998, 7: 119-125.
33. SHORVON S. Models of economic appraisals in epilepsy. In: Economic evaluation of epilepsy management. PACHLATKO C., BERAN R. G., LIBBEY John, 1996.
34. SHORVON S. Epidemiology, classification, natural history, and genetics of epilepsy. The Lancet, 1990, 336 (July 14): 93-96.
35. SILFVENIUS H. Economic costs of epilepsy - Treatment benefits. Surgical Treatment of Epilepsy, 1996, 136-154.
36. SWINGLER R. J., DAVIDSON D. L. W., ROBERTS R. C., MOULDING F. The cost of epilepsy in patients attending a specialist epilepsy service. Seizure, 1994, 3: 115-120.